To know where you’re going, look at where you’ve been
By: Debbie Feinstein, Bureau of Competition | Feb 23, 2017 4:46PM
Yesterday, I spoke to a group of antitrust practitioners and those involved in healthcare policy at AAI’s Healthcare Roundtable, where I discussed past and present FTC work to promote competition in healthcare markets.
Continue Reading To know where you’re going, look at where you’ve been
By: Jamie Towey, Bureau of Competition | Mar 30, 2016 3:41PM
For more than 15 years, one of the FTC’s top priorities has been to put an end to anticompetitive reverse-payment settlements between brand-name drug makers and their potential generic rivals. In our view, these settlements are anticompetitive agreements not to compete in which the brand pays the generic to refrain from marketing a lower cost, generic product for a period of time.
